References

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

10.1093/eurheartj/ehab309 · 2021 · External reference

Inflammation, cholesterol, Lipoprotein(a), and 30-Year cardiovascular outcomes in women

10.1056/nejmoa2405182 · 2024 · External reference

Interleukin-6 signaling and Anti-Interleukin-6 therapeutics in cardiovascular disease

10.1161/circresaha.121.319077 · 2021 · External reference

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

10.1016/s0140-6736(09)61717-7 · 2010 · External reference

Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein

10.1056/nejmoa0807646 · 2008 · External reference

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

10.1016/s0140-6736(17)32814-3 · 2018 · External reference

The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease - a systematic review and meta-analysis

2025 · External reference

Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association

10.1161/atv.0000000000000147 · 2022 · External reference

Lipoprotein(a) as a pharmacological target: premises, promises, and prospects

10.1161/circulationaha.124.069210 · 2025 · External reference

Risk assessment for cardiovascular disease with nontraditional risk factors: US preventive services task force recommendation statement

10.1001/jama.2018.8359 · 2018 · External reference

Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK biobank

10.1016/j.atherosclerosis.2023.117437 · 2024 · External reference

Lipoprotein(a), C-Reactive protein, and cardiovascular risk in primary and secondary prevention populations

10.1001/jamacardio.2023.5605 · 2024 · External reference

10.1161/circulationaha.124.071269

10.1161/circulationaha.124.071269 · 2025 · External reference

10.1093/eurheartj/ehab484

10.1093/eurheartj/ehab484 · 2021 · External reference

UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age

10.1371/journal.pmed.1001779 · 2015 · External reference

The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

10.1016/s0140-6736(07)61602-x · 2007 · External reference

C-Reactive protein and risk of incident heart failure in patients with cardiovascular disease

10.1016/j.jacc.2023.05.035 · 2023 · External reference

Unresolved reference

2019 · External reference

Unresolved reference

2022 · External reference

Causes of death in people with cardiovascular disease: a UK biobank cohort study

10.1161/jaha.121.023188 · 2021 · External reference

Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2

10.1093/eurjpc/zwad187 · 2023 · External reference

Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use

10.1186/s41073-016-0007-6 · 2016 · External reference

Prognostic impact of high-sensitivity C-Reactive protein in patients undergoing percutaneous coronary intervention according to BMI

10.1016/j.jcin.2020.09.024 · 2020 · External reference

Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events

10.1093/eurheartj/ehaf281 · 2025 · External reference

How to interpret statistical models using marginaleffects for R and python

10.18637/jss.v111.i09 · 2024 · External reference

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

10.1016/s0140-6736(23)00215-5 · 2023 · External reference

Low-dose colchicine for secondary prevention of coronary artery disease

10.1016/j.jacc.2023.05.055 · 2023 · External reference

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis society consensus statement

10.1093/eurheartj/ehac361 · 2022 · External reference

Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank

10.1161/atvbaha.120.315291 · 2021 · External reference

Lipoprotein(a) for risk assessment in patients with established coronary artery disease

10.1016/j.jacc.2013.09.042 · 2014 · External reference

Association of Lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial

10.1001/jamacardio.2017.3833 · 2018 · External reference

Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database

10.1093/eurheartj/ehaf297 · 2025 · External reference

Sex differences in the intensity of statin prescriptions at initiation in a primary care setting

10.1136/heartjnl-2023-323722 · 2024 · External reference

Sex differences in the use of statins in community practice

2019 · External reference

Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-norfolk study

10.1093/eurheartj/ehaf209 · 2025 · External reference

Association of Lipoprotein(a) and Interleukin-6 with cardiovascular risk: MESA and UK biobank

10.1016/j.jacc.2025.08.101 · 2025 · External reference

Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER study

10.1373/clinchem.2008.120642 · 2009 · External reference